Dry Eye Disease – Medical Alley Association

Dry Eye Disease

SilkTech Biopharmaceuticals Completes Enrollment of Phase 2B Clinical Trial of SDP-4 for the Treatment of the Signs and Symptoms of Dry Eye Disease

MINNEAPOLIS, MN— August 6, 2019 — SilkTech Biopharmaceuticals, a biotechnology company focused on the development of novel therapies to treat Dry Eye Disease (DED), today announced the completion of their Phase 2B clinical trial enrollment to assess the safety and efficacy of the company’s SDP-4 ophthalmic eye-drop formulation to treat the signs and symptoms of DED. […]

SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA; Phase 2 Clinical Trial Initiated for Patients with Dry Eye Disease

Milestone Results in $6.2 Million in Additional VC Funding Minneapolis, MN – April 16, 2019 – PRWeb – SilkTech Biopharmaceuticals, a company devoted to improving eye health through the development of silk-derived protein biotherapeutics for the targeted treatment of Dry Eye Disease (DED), today announced the company has received clearance of its Investigational New Drug […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER